uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).
Show others and affiliations
2014 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 3Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
2014. Vol. 32, no 3
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-224776ISI: 000333682100481OAI: oai:DiVA.org:uu-224776DiVA: diva2:718806
Conference
Gastrointestinal Cancers Symposium, JAN 16-18, 2014, San Francisco, CA
Available from: 2014-05-22 Created: 2014-05-20 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Authority records BETA

Glimelius, Bengt

Search in DiVA

By author/editor
Glimelius, Bengt
By organisation
Oncology
In the same journal
Journal of Clinical Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 367 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf